Monthly Archives: April 2016

Moving From Academia To Successful Biotech: Optimizing Tech Transfer
April 26, 2016

University tech transfer offices play a central role in the biotech ecosystem, as the successful commercialization of an academic discovery is the aspiration of many young startups. Navigating – and optimizing – this tech transfer process is therefore critical to the

1 Comment

Unpredictable Precedent: Bread, Circuses, And The Termination of Pfizer-Allergan
April 12, 2016

Last week, when the Treasury effectively scuttled the Pfizer-Allergan merger, there was much rejoicing: politicians and pundits alike were thrilled that tax inversion greed had been stopped, and that companies like Pfizer would have to “pay their fair share.”  Investors

Leave a comment

Raising Capital As A Private Biotech: Insights From Unum Therapeutics’ Series B Round
April 6, 2016

This blog was written by Christiana Stamoulis, CFO and Head of Corporate Development at Unum, as part of the “From The Trenches” feature of LifeSciVC. In June 2015 Unum Therapeutics closed a $65M a Series B round, bringing in capital

Leave a comment

Nimbus Delivers Its Apollo Mission: A $1.2B Gilead Partnership
April 4, 2016

Today Gilead announced the acquisition of Nimbus’ lead program targeting NASH and related metabolic disorders for $400M upfront and up to another $800M in development and regulatory milestones (here). This transformative deal is the culmination of over five years of work on

Leave a comment